In Phase I clinical trials , dietary curcumin was shown to exhibit poor bioavailability , exhibited by rapid metabolism , low levels in plasma and tissues , and extensive rapid excretion , factors that make its in vivo activity poorly under
Daily consumption of curcumin over a 3-month period of up to 12 grams is safe in humans .